Type 1 Diabetes (Juvenile Diabetes) is an indication for drug development with over 350 pipeline drugs currently active. According to GlobalData, preregistered drugs for Type 1 Diabetes (Juvenile Diabetes) have a 71.43% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Type 1 Diabetes (Juvenile Diabetes) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Type 1 Diabetes (Juvenile Diabetes) overview

Type 1 diabetes, often referred to as juvenile diabetes, is a chronic autoimmune condition where the body’s immune system attacks and destroys insulin-producing cells in the pancreas. Unlike type 2 diabetes, which typically develops later in life and is often associated with lifestyle factors, type 1 diabetes usually manifests in childhood or adolescence. Individuals with type 1 diabetes require lifelong insulin therapy to manage their blood sugar levels effectively. Despite advances in treatment and technology, living with type 1 diabetes requires careful monitoring of blood glucose levels, insulin administration, and dietary management to prevent complications such as diabetic ketoacidosis and long-term organ damage. Ongoing research aims to improve therapies and find a cure for this challenging condition.

For a complete picture of PTSR and LoA scores for drugs in Type 1 Diabetes (Juvenile Diabetes), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.